Abstract 1834P
Background
The first conversational AI Cancer mentor app was recently launched by Belong.life, a global oncology social network for cancer patients (pts) and caregivers. The app objectives are to provide uninterrupted support and guidance with empathetic, relevant information in cancer management. Belong’s unique and large datasets of pts to physicians and pts to pts interactions provide the basis for the AI platform, adding information from current guidelines, supplying solid up to date data with wide understanding of pts diverse cancer journeys.
Methods
Belong members enquiries, replied by the AI Cancer mentor were validated by 9 oncology experts in solid and haematological cancers, affiliated to various medical centres. 578 member enquiries coupled with the AI Cancer mentor replies, were randomly chosen and distributed according to cancer groups: Breast, Gastrointestinal, Pancreatic, Genitourinary, Musculoskeletal, Haematology and Radiation therapy. The oncologists assessed the AI mentor accuracy of recommendations by relevance and helpfulness, aligning them to evidence-based medicine and current international guidelines.
Results
527/578 (91.18%) AI Cancer mentor replies received a positive validation for their suitable and relevant recommendations. Conversely, 46/578 (7.96%) received a negative validation, while only 5/578 (0.86%) graded as not helpful. Minor variations were noticed in the cancer groups, with positive validations as follows: Genitourinary 100%, Breast 95.7%, Pancreatic 92%, Musculoskeletal 91.2%, Radiation therapy 88%, Gastrointestinal 86.4%, Haematological cancers 84%.
Conclusions
The reported accuracy (91.18%) on 578 pts enquiries and AI Cancer mentor replies, evaluated by a multi-disciplinary, multi-institutional oncologist group, are very promising, indicating that the Belong’s AI cancer mentor provides valuable and reliable recommendations. The findings offered insights into the AI mentor’s performance across a wide group of cancers. Based on this report, the addition of an AI mentor in cancer care, provides helpful, relevant guidance on pts diverse cancer journeys, while supporting oncologists in their pts management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Haikin, D.A. Vorobiof: Financial Interests, Personal, Full or part-time Employment: Belong.life. All other authors have declared no conflicts of interest.
Resources from the same session
1874P - Time to vomiting after chemotherapy in association with number of emetic risk factors among breast cancer patients receiving highly emetogenic chemotherapy
Presenter: Winnie Yeo
Session: Poster session 12
1875P - Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience
Presenter: Onur Bas
Session: Poster session 12
1877P - Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis
Presenter: Neha Pathak
Session: Poster session 12
1878P - Efficacy of surgical gloves (SG) as compression therapy to prevent oxaliplatin-induced peripheral neuropathy (PN): The ELEGANT trial
Presenter: Aurélia JOUREAU-CHABERT
Session: Poster session 12
1879P - Effectiveness of intravenous fosnetupitant & palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: Subgroup analysis from a phase IV Indian study
Presenter: Arun Kumar Verma
Session: Poster session 12
1880P - Antiemetic prophylaxis during chemoradiation: Sub-study of the GAND-emesis trial identifying dosimetric predictors for vomiting
Presenter: Anika Johannsdottir
Session: Poster session 12
1881P - Enhancing chemotherapy-induced nausea and vomiting management: Insights into guideline adherence and patient outcomes
Presenter: Suresh Attili
Session: Poster session 12
1882P - Awareness of chemotherapy induced nausea and vomiting and adherence to guidelines: A multinational and multicenter survey
Presenter: Ricardo Caponero
Session: Poster session 12
1883P - Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial
Presenter: Emanuela Risi
Session: Poster session 12
1884P - Development and validation of a prediction tool for severe treatment-related toxicities in older cancer patients on systemic treatment (TR-TRM)
Presenter: Wendy Chan
Session: Poster session 12